HMGCR and neoplasm: Nonetheless, the successful clinical translation of HMGCR inhibitors as immunotherapy adjuvants will require a deeper mechanistic understanding of how to selectively harness ferroptosis to stimulate anti-tumor immunity while minimizing unintended effects on immune effector cells.